Navigation Links
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
Date:12/7/2008

(60 percent) and nausea (52 percent).

-- There were no reports of deep-vein thrombosis or pulmonary embolism.

-- As initial therapy, all patients had a partial response or better, with 36% of patients achieveing a CR.

"We are committed to advancing multiple myeloma treatment that delivers the best patient outcomes," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "The tolerability of this novel four-drug combination allows us to study its efficacy relative to two of the most active three-drug regimens for previously untreated multiple myeloma patients."

During Phase I, patients received VELCADE at 1.3 mg/m(2) on days 1, 4, 8 and 11 on a 21-day cycle for up to eight cycles; dexamethasone at 40 mg on days 1, 8 and 15; lenalidomide at 15 mg on days 1 through 14; and cyclophosphamide at 100, 200, 300, 400 or 500 mg/m(2) on days 1 and 8 for up to eight 21-day cycles. This was followed by VELCADE at 1.3 mg/m(2) on days 1, 8, 15 and 22 for four 42-day maintenance cycles. The primary endpoint of this Phase I trial was the determination of the maximum tolerated dose of cyclophosphamide in combination with VcDR. The primary endpoints of the ongoing Phase II portion of the trial are complete response and very good partial response rates, while the secondary endpoints include progression-free survival, overall survival, safety and tolerability.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the median age of onset is 70 years), recent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000 new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is co-developed by Mi
'/>"/>

SOURCE Millennium: The Takeda Oncology Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014 With advancements in ... MRI market is seeing new growth, according to ... scans account for the majority of market volume, ... of images, which are creating opportunities for more sophisticated ... is growing at a rate of 4%, with ...
(Date:12/17/2014)...  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) ... (USPTO) has issued a key patent covering ImmunoCellular,s ... targeting six tumor antigens that are commonly expressed ... 8,871,211, which issued October 28, 2014, include methods ... cell composition comprising peptide epitopes of the six ...
(Date:12/17/2014)... Ga. and RALEIGH, N.C. ... Trial Marketing Communications, LLC (CTMC), and Integrated Clinical ... patient recruitment and retention for clinical trials announce ... Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS will ... retention services to pharmaceutical, biotechnology and medical device ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
... DATA), a technology and services company focused on global ... NTT DATA signed a non-exclusive license to resell DATATRAK ... an existing value-added reseller of DATATRAK ONE™ and Enterprise ... its reach into China to deliver clinical trials with ...
... Medical Inc. (OTCBB:ONCS), which is developing its advanced-stage ... tumor cancers, issued the following letter to Shareholders today: ... Dear Shareholder: As we near the mid-point ... for the year. I want to review the key ...
Cached Medicine Technology:NTT DATA Licenses DATATRAK ONE™ for China 2NTT DATA Licenses DATATRAK ONE™ for China 3OncoSec Medical Issues Letter to Shareholders 2OncoSec Medical Issues Letter to Shareholders 3OncoSec Medical Issues Letter to Shareholders 4OncoSec Medical Issues Letter to Shareholders 5
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... , THURSDAY, Oct. 6 (HealthDay News) -- ,Food ads have ... lessen that effect, according to a new study. It ... cartoons, with a commercial between each cartoon. Half the children ... half saw a commercial for French fries. After watching ...
... CHAPEL HILL, N.C. -- Cam Patterson, MD, MBA, division ... at Chapel Hill School of Medicine has been named ... Association Judah Folkman Award in Vascular Biology. The ... at mid-career (within fifteen years of their first faculty ...
... By Mary Brophy Marcus HealthDay Reporter , ... therapy given shortly after a kidney transplant allows some patients ... from attacking the new organ, according to a small new ... transplants are common in the United States and while they ...
... who had been given DES, the first synthetic form of ... while in the womb (in utero) is associated with many ... pre-cancerous conditions. The results of this analysis, conducted by researchers ... Institutes of Health, and collaborators across the country, were published ...
... By Jenifer Goodwin HealthDay Reporter , WEDNESDAY, ... mice whose symptoms closely mimic autism in humans. ... the mice in this study come closer to mirroring ... in humans, said senior study author Matthew Anderson, an ...
... Oct. 5 (HealthDay News) -- Women whose mothers were ... increased risk for fertility problems and cancer as they ... U.S. National Cancer Institute "illustrates that the effects of ... decades to be fully appreciated or recognized in humans," ...
Cached Medicine News:Health News:TV Ads Whet Kids' Appetite for Junk Food 2Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 2Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 3Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 4Health News:Women exposed to diethylstilbestrol in the womb face increased cancer risk 2Health News:Women exposed to diethylstilbestrol in the womb face increased cancer risk 3Health News:Scientists Engineer Mice That Have Autism 2Health News:Scientists Engineer Mice That Have Autism 3Health News:Health Woes Still Strike Women Exposed to Banned Pregnancy Drug 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: